U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer

Harpreet Singh, Richard Pazdur, Laleh Amiri‐Kordestani et al.|Clinical Cancer Research|2018

Cited by 98